A PHASE 3B LONG-TERM EFFICACY AND SAFETY EXTENSION STUDY OF BARZOLVOLIMAB IN PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA WHO HAVE COMPLETED CDX0159-12 OR CDX0159-13 (EMBARQ-CSULTE)
- Registry ID
- CDX0159-17
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- CELLDEX THERAPEUTICS INC
- Start date
- 2026-05-08
- Last update
- 2026-02-27
Conditions
- CHRONIC SPONTANEOUS URTICARIA
Related clinical trials
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE
EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS
URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT
(EMBARQ - CSU1)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT (EMBARQ - CSU2)
- AN OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PK,
IMMUNOGENICITY, AND CLINICAL RESPONSE OF MULTIPLE DOSES OF IV AK006 IN
SUBJECTS WITH H1 ANTIHISTAMINE REFRACTORY CHRONIC SPONTANEOUS URTICARIA
COMPLETING STUDY AK006-001
- A GLOBAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, PHASE 3B STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB 25 MG B.I.D. IN COMPARISON TO PLACEBO WITH OMALIZUMAB 300 MG EVERY 4 WEEKS AS ACTIVE CONTROL OVER 52 WEEKS IN ADULT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED BY SECOND-GENERATION H1-ANTIHISTAMINES, AND AN OPEN-LABEL 52-WEEK OPTIONAL EXTENSION TO ASSESS LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB 25
- A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL AND OPEN-LABEL EXTENSION STUDY FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT CYCLES TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB (LOU064) IN ADULT CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED THE PRECEDING REMIBRUTINIB PHASE 3 STUDIES
- "A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED PILOT AND DOSE-RANGING STUDY OF MTPS9579A IN PARTICIPANTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA
View on source registry